UA103807C2 - Замещенные бензамидные производные как активаторы глюкокиназы (gk) - Google Patents

Замещенные бензамидные производные как активаторы глюкокиназы (gk)

Info

Publication number
UA103807C2
UA103807C2 UAA201200651A UAA201200651A UA103807C2 UA 103807 C2 UA103807 C2 UA 103807C2 UA A201200651 A UAA201200651 A UA A201200651A UA A201200651 A UAA201200651 A UA A201200651A UA 103807 C2 UA103807 C2 UA 103807C2
Authority
UA
Ukraine
Prior art keywords
glucokinase
compounds
benzamide derivatives
substituted benzamide
activators
Prior art date
Application number
UAA201200651A
Other languages
English (en)
Ukrainian (uk)
Inventor
Раджендра Харул
Мукул Р. Джаин
Панкайи Р. Пател
Original Assignee
Кадила Хелткере Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кадила Хелткере Лимитед filed Critical Кадила Хелткере Лимитед
Publication of UA103807C2 publication Critical patent/UA103807C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Данное изобретение касается замещенных бензамидных производных общей формулы I и их фармацевтически приемлемых солей, фармацевтически приемлемых сольватов, энантиомеров, диастереомеров, пролекарств, метаболитов и полиморфных форм и может быть полезным для лечения болезненных состояний, медиированных глюкокиназой. Раскрытые соединения могут быть использованы для снижения уровней глюкозы крови и для повышения секреции инсулина при лечении диабета типа II. Изобретение также касается способов получения соединений согласно изобретению, фармацевтических композиций, которые содержат соединения, и их использования.(I)
UAA201200651A 2009-07-31 2010-07-22 Замещенные бензамидные производные как активаторы глюкокиназы (gk) UA103807C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1767MU2009 2009-07-31
PCT/IN2010/000486 WO2011013141A2 (en) 2009-07-31 2010-07-22 Substituted benzamide derivatives as glucokinase (gk) activators

Publications (1)

Publication Number Publication Date
UA103807C2 true UA103807C2 (ru) 2013-11-25

Family

ID=43432167

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201200651A UA103807C2 (ru) 2009-07-31 2010-07-22 Замещенные бензамидные производные как активаторы глюкокиназы (gk)

Country Status (16)

Country Link
US (1) US8835469B2 (ru)
EP (1) EP2459554B1 (ru)
JP (1) JP2013500961A (ru)
KR (1) KR20120047960A (ru)
CN (1) CN102482267B (ru)
AU (1) AU2010277171B2 (ru)
CA (1) CA2768232A1 (ru)
DK (1) DK2459554T3 (ru)
EA (1) EA201270217A1 (ru)
MX (1) MX2012001228A (ru)
MY (1) MY156175A (ru)
NZ (1) NZ598232A (ru)
SG (1) SG178043A1 (ru)
UA (1) UA103807C2 (ru)
WO (1) WO2011013141A2 (ru)
ZA (1) ZA201200561B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
CN106176776A (zh) * 2016-07-04 2016-12-07 华北制药集团新药研究开发有限责任公司 葡萄糖激酶激动活性化合物的医药用途
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
EP4382529A1 (en) 2022-12-07 2024-06-12 Bayer Consumer Care AG A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
AU5227001A (en) 2000-05-03 2001-11-12 Hoffmann La Roche Hydantoin-containing glucokinase activators
PT1305301E (pt) 2000-07-20 2005-09-30 Hoffmann La Roche Benzeno-acetamidas alfa-acilo e alfa-heteroatomo-substituidas activadoras da glucocinase
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
CN100591671C (zh) * 2003-02-26 2010-02-24 万有制药株式会社 杂芳基氨基甲酰基苯衍生物
MXPA05009059A (es) * 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
BRPI0507746A (pt) 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
CA2554686A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Compounds
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
GB0423043D0 (en) 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
EP2027113A1 (en) 2005-07-09 2009-02-25 AstraZeneca AB Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
FR2907720B1 (fr) 2006-10-25 2009-12-18 Renault Sas Transmission a derivation de puissance et blocage de l'arbre d'entree de la transmission entraine par le moteur thermique d'un vehicule.

Also Published As

Publication number Publication date
JP2013500961A (ja) 2013-01-10
KR20120047960A (ko) 2012-05-14
SG178043A1 (en) 2012-03-29
MX2012001228A (es) 2012-04-20
EP2459554A2 (en) 2012-06-06
CN102482267A (zh) 2012-05-30
NZ598232A (en) 2013-08-30
EP2459554B1 (en) 2013-09-18
DK2459554T3 (da) 2014-01-06
US20120184544A1 (en) 2012-07-19
AU2010277171A1 (en) 2012-02-09
EA201270217A1 (ru) 2012-09-28
CN102482267B (zh) 2014-12-03
US8835469B2 (en) 2014-09-16
MY156175A (en) 2016-01-15
WO2011013141A2 (en) 2011-02-03
WO2011013141A3 (en) 2011-03-24
AU2010277171B2 (en) 2013-02-07
ZA201200561B (en) 2012-09-26
CA2768232A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
MX2010009922A (es) Activadores de piridazinona glucocinasa.
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
PH12015502323A1 (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
MX2009011816A (es) Derivados de piridina.
WO2009047798A3 (en) Acetamide derivatives as glucokinase activators, their process and medicinal applications
WO2011056985A3 (en) Substituted heterocyclic compounds
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
MX2011009493A (es) Compuestos para el tratamiento de trastornos metabolicos.
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
GEP20156319B (en) Asymmetric ureas and medical uses thereof
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
GEP20135793B (en) Heteroaryls amide derivatives and their use as glucokinase activators
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
MX2013005535A (es) Compuesto de 3- (amino-aril) -piridina.
EA201070864A1 (ru) Новые гетероциклические соединения
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
PH12014502570A1 (en) Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
PH12014502567A1 (en) Piperidine derivatives for gpr119 agonist
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
WO2011070592A3 (en) Novel sugar derivatives as sglt2 inhibitors
NZ598232A (en) Substituted benzamide derivatives as glucokinase (gk) activators
MX2009002906A (es) Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia.